Tech Center 1600 • Art Units: 1600 1642 1643 1644 1646 1671
This examiner grants 62% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17611019 | METHODS AND COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER | Final Rejection | Board of Regents, The University of Texas System |
| 17597582 | Functional Binders Synthesized and Secreted by Immune Cells | Non-Final OA | NATIONAL UNIVERSITY OF SINGAPORE |
| 18262173 | IMMUNOMODULATORY ANTIBODIES AND USES THEREOF | Non-Final OA | OncoResponse, Inc. |
| 17993567 | COMBINATION THERAPIES OF HDAC INHIBITORS AND PD-L1 INHIBITORS | Final Rejection | HUYABIO International, LLC |
| 18185649 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | Non-Final OA | Immatics Biotechnologies GmbH |
| 17998605 | SARS-COV2 NEUTRALIZING SINGLE DOMAIN ANTIBODY CONSTRUCTS | Non-Final OA | REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 16898008 | Compositions and Methods for Cancer Immunotherapy | Non-Final OA | Mural Oncology, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy